(VIANEWS) – Camden Property Trust (CPT), Abbott Laboratories (ABT), Pacific Premier Bancorp (PPBI) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio so far. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Camden Property Trust (CPT)
67.37% Payout Ratio
Camden Property Trust, an S&P 400 Company, is a real estate company primarily engaged in the ownership, management, development, redevelopment, acquisition, and construction of multifamily apartment communities. Camden owns interests in and operates 167 properties containing 56,850 apartment homes across the United States. Upon completion of 7 properties currently under development, the Company's portfolio will increase to 59,104 apartment homes in 174 properties. Camden has been recognized as one of the 100 Best Companies to Work For® by FORTUNE magazine for 13 consecutive years, most recently ranking #18. The Company also received a Glassdoor Employees' Choice Award in 2020, ranking #25 for large U.S. companies.
Earnings Per Share
As for profitability, Camden Property Trust has a trailing twelve months EPS of $5.67.
PE Ratio
Camden Property Trust has a trailing twelve months price to earnings ratio of 19.62. Meaning, the purchaser of the share is investing $19.62 for every dollar of annual earnings.
Yearly Top and Bottom Value
Camden Property Trust’s stock is valued at $111.27 at 08:23 EST, way under its 52-week high of $153.45 and way higher than its 52-week low of $97.74.
2. Abbott Laboratories (ABT)
58.36% Payout Ratio
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Earnings Per Share
As for profitability, Abbott Laboratories has a trailing twelve months EPS of $3.27.
PE Ratio
Abbott Laboratories has a trailing twelve months price to earnings ratio of 33.5. Meaning, the purchaser of the share is investing $33.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.93%.
Moving Average
Abbott Laboratories’s value is higher than its 50-day moving average of $104.12 and higher than its 200-day moving average of $105.33.
3. Pacific Premier Bancorp (PPBI)
44.9% Payout Ratio
Pacific Premier Bancorp, Inc. operates as the bank holding company for Pacific Premier Bank that provides banking services to businesses, professionals, real estate investors, and non-profit organizations. The company accepts deposit products, such as checking, money market, and savings accounts; and certificates of deposit. Its loan portfolio includes commercial real estate owner and non-owner-occupied, multifamily, construction and land, franchise real estate secured, small business administration (SBA), and SBA paycheck protection program loans; revolving lines or credit, term loans, seasonal loans, and loans secured by liquid collateral; one-to-four family and home equity lines of credit loans; and savings account secured loans and auto loans. The company also offers cash management, electronic banking, treasury management, and online bill payment services. It operates 61 full-service depository branches located in Arizona, California, Nevada, Oregon, and Washington. Pacific Premier Bancorp, Inc. was founded in 1983 and is headquartered in Irvine, California.
Earnings Per Share
As for profitability, Pacific Premier Bancorp has a trailing twelve months EPS of $2.94.
PE Ratio
Pacific Premier Bancorp has a trailing twelve months price to earnings ratio of 6.16. Meaning, the purchaser of the share is investing $6.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.95%.
Yearly Top and Bottom Value
Pacific Premier Bancorp’s stock is valued at $18.12 at 08:23 EST, way below its 52-week high of $37.50 and higher than its 52-week low of $17.53.
Moving Average
Pacific Premier Bancorp’s worth is way below its 50-day moving average of $24.24 and way under its 200-day moving average of $31.17.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 4, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 6.9%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.3%, now sitting on 780.52M for the twelve trailing months.
4. A10 Networks (ATEN)
35% Payout Ratio
A10 Networks, Inc. provides networking solutions in the United States, Japan, other Asia Pacific, and EMEA countries. The company offers Thunder Application Delivery Controller (ADC) that provides advanced server load balancing; Lightning ADC, a cloud-native software-as-a-service platform to boost the delivery and security of applications and micro services; and Thunder Carrier Grade Networking product, which offers standards-compliant address and protocol translation services for service provider networks. It also provides Thunder Threat Protection System (TPS) for the protection of networks and server resources against massive distributed denial of service attacks; Thunder Secure Sockets Layer (SSL) Insight solution that decrypts SSL-encrypted traffic and forwards it to a third-party security device for deep packet inspection; and Thunder Convergent Firewall, which addresses various critical security capabilities in one package by consolidating various security and networking functions in a single appliance. In addition, the company offers intelligent management and automation tools comprising harmony controller that provides intelligent management, automation, and analytics for secure application delivery in multi-cloud environment; and aGalaxy TPS, a multi-device network management solution. The company delivers its solutions on optimized hardware appliances, bare metal software, containerized software, virtual appliances, and cloud-native software. It serves cloud providers, service providers, government organizations, and enterprises in the telecommunications, technology, industrial, retail, government, financial, gaming, and education industries. The company markets its products through sales organizations, as well as distribution channel partners, including distributors, value added resellers, and system integrators. A10 Networks, Inc. was incorporated in 2004 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, A10 Networks has a trailing twelve months EPS of $0.6.
PE Ratio
A10 Networks has a trailing twelve months price to earnings ratio of 23.57. Meaning, the purchaser of the share is investing $23.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.06%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.9%, now sitting on 280.34M for the twelve trailing months.
Sales Growth
A10 Networks’s sales growth is negative 9% for the current quarter and negative 3.7% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 7.7% and 5.9%, respectively.
5. Pfizer (PFE)
31.76% Payout Ratio
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Pfizer has a trailing twelve months EPS of $5.05.
PE Ratio
Pfizer has a trailing twelve months price to earnings ratio of 7.38. Meaning, the purchaser of the share is investing $7.38 for every dollar of annual earnings.
Revenue Growth
Year-on-year quarterly revenue growth declined by 28.8%, now sitting on 92.95B for the twelve trailing months.
Moving Average
Pfizer’s worth is under its 50-day moving average of $40.00 and way under its 200-day moving average of $45.14.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Pfizer’s EBITDA is 2.5.
Previous days news about Pfizer (PFE)
- According to Zacks on Friday, 12 May, "In the last five trading sessions, Lilly rose the most (up 1.7%), while Pfizer declined the most (1.7%).", "In the past six months, Novartis has risen the most (23.9%), while Pfizer has declined the most (23.7%)."
